A promising development in the creation of a vaccine to prevent malaria

Cialis

Two groups of researchers from Michigan State University and from the College of Osteophatic Medicine, both discovered that by using immune stimulating agents in the creation of vaccines stimulates the increasing action of the immune system to fight against malaria disease.
Malaria is a disease occurring after the bite of a mosquito carrying the "Plasmodium" genus. After the bite, this gene multiplies in the red blood cells causing fever, headaches, and without a treatment usually leads to coma, and eventually death.
This disease is currently the cause of death for over a million people annually, and the most affected area is Sub-Saharan Africa but can also be found in certain areas of Asia and America. Most commonly, this disease is considered to be affecting the most poor areas because the people living here lack resources to protect themselves such as mosquito nets.
Although many other research groups are conducted for developing a vaccine against this disease, the study group from the College of Osteophatic Medicine, conducted by Andrea Amalfitano, is focusing their research on a protein of the malaria parasite, called Circumsporozoite Protein or CSP.
This protein is considered to be the key in developing an immune response to the parasite because from the results collected in the past researches, people infected with malaria several times, developed a higher level of immune response to this protein.
Basically, this vaccine is looking to stimulate the immune system of the person by inducing a higher amount of genes called genetic agents.
The research so far has been conducted on mice and the vaccine had two genes added, called rEA and EAT-2.
According to the results of the study, rEA weakened the ability of the animal to generate a higher immune response, unlike EAT-2 which surpassed the scientists' expectations and was able to create a much higher immune response.
The next step of the research is to create a vaccine which has a main gene-adjuvant only EAT-2 and follow the results on mice. If the results will be satisfactory, the study will continue with humans.
The full results of the study have been published in the PLos ONE.